Zanzalintinib
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research[1][2].
Product Specifications
CAS Number
2367004-54-2
Product Name Alternative
XL092
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
C-Met/HGFR; TAM Receptor; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zanzalintinib.html
Purity
99.91
Solubility
DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=CC2=C(OC3=CC=C(NC(C4(CC4)C(NC5=CC=C(C=C5)F)=O)=O)C=C3)C=CN=C2C=C1OC)NC
Molecular Formula
C29H25FN4O5
Molecular Weight
528.53
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Axl; Mer; VEGFR2/KDR/Flk-1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MART-1 / Melan-A (M2-7C10), CF405S conjugate, 0.1mg/mL
CD16 (C16/1045), CF405S conjugate, 0.1mg/mL
Cytokeratin 17 (E3), CF647 conjugate, 0.1mg/mL
